Kos Pharmaceuticals and Takeda Pharmaceuticals reach agreement to co-promote Niaspan and Advicor

Share this article:

Kos Pharmaceuticals and Takeda Pharmaceuticals have reached a three-year agreement to co-promote Kos' Niaspan and Advicor in the U.S. market. The agreement adds more than 1,000 Takeda sales representatives to the existing Kos sales force to detail the two products developed by Kos for treating cholesterol disorders. The increased promotional effort is expected to significantly enhance the value of Kos' cholesterol franchise within the U.S., the largest cholesterol market in the world. For Takeda, the agreement fills current sales force capacity while allowing the company to continue to grow its franchise product, Actos.

The co-promotion arrangement has a three-year term commencing January 2004 and provides for residual payments to Takeda after the three years, if the parties do not renew the agreement.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.